High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer
about
RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancerConstructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression.Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.TPX2 is a prognostic marker and contributes to growth and metastasis of human hepatocellular carcinoma.Upregulation of TPX2 by STAT3: identification of a novel STAT3 binding site.Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer.Using RNA sequencing for identifying gene imprinting and random monoallelic expression in human placenta.Mitotic Stress and Chromosomal Instability in Cancer: The Case for TPX2.Beyond taxol: microtubule-based treatment of disease and injury of the nervous system.TPX2: of spindle assembly, DNA damage response, and cancer.Non-alcoholic fatty liver disease in mice with heterozygous mutation in TMED2.Target protein for Xklp2 (TPX2), a microtubule-related protein, contributes to malignant phenotype in bladder carcinoma.Targeted TPX2 increases chromosome missegregation and suppresses tumor cell growth in human prostate cancer.AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination.Aberrant DNA-PKcs and ERGIC1 expression may be involved in initiation of gastric cancer.
P2860
Q27316858-7A69D5D2-A582-4D36-8369-74FC1B6EC55DQ31130674-1ADAF060-B3AC-4B1A-8CCE-2A78610C0815Q34302881-9E6EAFA0-2FF5-404B-8F4D-C38252E1F3DAQ34486752-3D10F329-4CE1-464C-B4C5-80C79B976AF8Q35424270-E59E95AA-6124-40E9-B533-058B2D4688F3Q35873154-8E8FAEA5-A9E2-4C90-A1FC-A30AC1E0A861Q36214937-46AE0A6F-751C-4E14-AA1A-A19446052200Q36796428-E912B53C-065C-42B9-BFA6-96A569BAF6B0Q37200301-4AC3D74A-C2BE-48AD-9CF5-B0A79EDD5B31Q38189984-E6ECA186-AE5E-4467-8711-1C030F419838Q38630243-D71DBA8A-A37E-47C2-A5C7-634FC8E1188EQ39122650-DA6252D8-DA61-4860-BBD9-6B9C701EE657Q41097100-649325E9-EF27-4602-8E9D-7C068FCEEA54Q41140861-C5C4CFA2-4E64-42BB-B91A-0270F9316A7FQ42358513-4AC787A2-271E-4CA4-9B0D-187DCCBBF1EF
P2860
High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
High-throughput transcriptomic ...... rug targets in prostate cancer
@ast
High-throughput transcriptomic ...... rug targets in prostate cancer
@en
High-throughput transcriptomic ...... rug targets in prostate cancer
@nl
type
label
High-throughput transcriptomic ...... rug targets in prostate cancer
@ast
High-throughput transcriptomic ...... rug targets in prostate cancer
@en
High-throughput transcriptomic ...... rug targets in prostate cancer
@nl
prefLabel
High-throughput transcriptomic ...... rug targets in prostate cancer
@ast
High-throughput transcriptomic ...... rug targets in prostate cancer
@en
High-throughput transcriptomic ...... rug targets in prostate cancer
@nl
P2093
P2860
P50
P1433
P1476
High-throughput transcriptomic ...... rug targets in prostate cancer
@en
P2093
John-Patrick Mpindi
Kalle A Alanen
Kristiina Iljin
Paula Vainio
P2860
P304
P356
10.1371/JOURNAL.PONE.0039801
P407
P577
2012-01-01T00:00:00Z